Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/7846
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kemal Celen, M. | - |
dc.contributor.author | Tekin Koruk, S. | - |
dc.contributor.author | Aygen, B. | - |
dc.contributor.author | Dal, T. | - |
dc.contributor.author | Karabay, O. | - |
dc.contributor.author | Tosun, S. | - |
dc.contributor.author | Koksal, I. | - |
dc.date.accessioned | 2019-08-16T12:32:46Z | |
dc.date.available | 2019-08-16T12:32:46Z | |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1840-0132 | - |
dc.identifier.uri | https://hdl.handle.net/11499/7846 | - |
dc.description.abstract | Aim To evaluate the characteristics of patients with hepatitis B virus (HBV) infection and summarize the treatment modalities. Methods By September 30, 2011 the data of 7871 HBsAg (+) patients were complied and analysed according to demographic and medical records (age, sex, laboratory tests, treatment with antiviral agents) in thirty centres of Turkey. Results Of the 7871 patients 3078 (39.1%) were females; mean (standard deviation) age was 35 (14) years, 3180 (40.4%) were HBsAg positive (+) after admission to a hospital, 1488 (18.9%) after blood donation and 967 (11.9%) were found during routine screening. The HBV prevalence among relatives of HBsAg (+) patients was 1764 (22.4%), and most frequently infected family members were siblings and mothers, 4961 (63.0%) and 2149 (27.3%), respectively). Anti-HDV was negative in 7407 94.1% of patients. Three-fourths of the patients 6383 (81.1%) were HBeAg negative (-). Mean (SD) ALT was 85.8 (266.4) U/L. Majority of patients, 5588 (71.0%) were chronic hepatitis-B patients under treatment, while 2283 (29.0%) were asymptomatic carriers without treatment and only 165 (2.1%) of patients were cirrhotic and 6612 (84.0%) of those were compensated. One-third of the patients 2983 (37.9%) were under a combined treatment, while others were under monotherapy. Lamivudine, entecavir and adefovir were the most frequently used oral therapies, used for 2583 (32.8%), 11.6% and 787 (10.0%) of patients, respectively), while 2975 (37.8%) of patients were under interferon treatment. Conclusion Hepatitis B is still a problem in our country. First task of the physicians and our state should be to prevent the development and spread of the disease with education and vaccination programs, safe blood transfusions, and control of barbers. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Medical Association of Zenica-Doboj Canton | en_US |
dc.relation.ispartof | Medicinski Glasnik | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Blood donor | en_US |
dc.subject | Hepadnaviridae infections | en_US |
dc.subject | Prevalence | en_US |
dc.subject | adefovir | en_US |
dc.subject | alanine aminotransferase | en_US |
dc.subject | alkaline phosphatase | en_US |
dc.subject | aspartate aminotransferase | en_US |
dc.subject | entecavir | en_US |
dc.subject | gamma glutamyltransferase | en_US |
dc.subject | interferon | en_US |
dc.subject | lamivudine | en_US |
dc.subject | antivirus agent | en_US |
dc.subject | adult | en_US |
dc.subject | article | en_US |
dc.subject | enzyme linked immunosorbent assay | en_US |
dc.subject | female | en_US |
dc.subject | hepatitis B | en_US |
dc.subject | human | en_US |
dc.subject | infection control | en_US |
dc.subject | infection risk | en_US |
dc.subject | liver function test | en_US |
dc.subject | major clinical study | en_US |
dc.subject | male | en_US |
dc.subject | prevalence | en_US |
dc.subject | radioimmunoassay | en_US |
dc.subject | Turkey (republic) | en_US |
dc.subject | Hepatitis B, Chronic | en_US |
dc.subject | Turkey | en_US |
dc.subject | Adult | en_US |
dc.subject | Antiviral Agents | en_US |
dc.subject | Female | en_US |
dc.subject | Humans | en_US |
dc.subject | Male | en_US |
dc.title | The characteristics of patients with chronic hepatitis B in Turkey | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 11 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.startpage | 94 | |
dc.identifier.startpage | 94 | en_US |
dc.identifier.endpage | 98 | en_US |
dc.authorid | 0000-0003-4270-3997 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.scopus | 2-s2.0-84893219442 | en_US |
dc.identifier.scopusquality | Q3 | - |
dc.owner | Pamukkale University | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
item.openairetype | Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | 06.01. Clinical Sciences | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu |
CORE Recommender
SCOPUSTM
Citations
9
checked on Nov 16, 2024
Page view(s)
42
checked on Aug 24, 2024
Google ScholarTM
Check
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.